Key Updates Needed in Chronic Spontaneous Urticaria Guidelines

Current guidelines suggest limiting diagnostic testing for chronic spontaneous urticaria when no clear cause is suspected, though biomarkers and biopsies are emerging as tools to predict treatment response and personalize care.

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

Increasing environmental events driven by climate change and human activity exacerbate allergy and asthma conditions, further compounded by exposure to persistent pollutants like per-and polyfluoroalkyl substances and microplastics.

Reducing the use of oral corticosteroids in patients with severe asthma is a pressing concern due to their associated adverse effects, health care costs, and impact on quality of life.

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease severity in adults.